2021-6-22 · Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐ intermediate‐1‐ intermediate‐2‐ and high‐risk myelofibrosis in JUMP a Phase 3b expanded‐access study
ISO4Frontiers in Oncology. Frontiers in Oncology ISO4 「Front. Oncol.」. ISO 4 —— Information and documentationRules for the abbreviation of title words and titles of publications . ISO4 .
2021-7-4 · FRONT ONCOL SCI " FRONT ONCOL " " FRONT ONCOL "
2014-8-18 · Purpose Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclophosphamide doxorubicin vincristine prednisone (CHOP) and results in a 5-year overall survival (OS) rate of less than 50 . This phase I open-label study evaluated the safety and activity of brentuximab vedotin administered sequentially with CHOP or in combination with CHP (CHOP without
Corrigendum Enhanced cytotoxic effects of combined valproic acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer cells Front Oncol. 3 (2013) 58. Doi 10.3389/fonc.2013.00058 Farhan S. Cyprian · Halema F. Al-Farsi · Semir Vranic ·
Journal of Oncology publishes research related to breast cancer lung cancer gastrointestinal cancer skin cancer head and neck cancer paediatric oncology neurooncology as well as genitourinary cancer.
2021-3-18 · Front. Oncol. 11 564799. doi 10.3389/fonc.2021.564799. Received 22 May 2020 Accepted 01 March 2021 Published 18 March 2021.
2021-7-17 · Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology particularly with experimental therapeutics with the field of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies in oncology and hematology. Topics covered include
2 days ago · The American Society of Clinical Oncology seeks to provide the highest-quality resources in education policy the pioneering of clinical research and above all
2020-11-10 · Background Erlotinib-based combination therapy leads to increased efficacy but also toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment tolerability but few evidences are available regarding its efficacy at reduced dose. This randomized phase-2 study intends to compare the efficacy and tolerability between lower dose erlotinib (100 mg/d) and standard
Front Oncol 10 (-) 598872 2020-12-09 online 2020-12-09 Bioinformatics Compute and Storage Service NGI Uppsala (SNP SEQ Technology Platform)
2020-11-10 · Background Erlotinib-based combination therapy leads to increased efficacy but also toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment tolerability but few evidences are available regarding its efficacy at reduced dose. This randomized phase-2 study intends to compare the efficacy and tolerability between lower dose erlotinib (100 mg/d) and standard
Main focuses of interest include Annals of Oncology the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology
Future Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors including our Accelerated Publication and Open Access services. Visit Oncology Central our free online community. Follow us on social media for the latest updates. Submit an article eToC Sign-up.
Oncology Reports is an international journal devoted to fundamental and applied research in oncology.
2021-7-18 · FRONT ONCOL Frontiers in Oncology 1435 56.61 Irregular 2.1 3.1
Front Oncol 10 (-) 598872 2020-12-09 online 2020-12-09 Bioinformatics Compute and Storage Service NGI Uppsala (SNP SEQ Technology Platform)
2021-6-1 · Front Oncol (2016) 6 61. doi 10.3389/fonc.2016.00061. PubMed Abstract CrossRef Full Text Google Scholar
2019-3-5 · Targeted therapies have allowed for an individualized treatment approach in non-small-cell lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy depend on genetic identification of personal tumor profiles. Tissue biopsy is the gold standard for molecular analysis but non-invasive or minimally invasive liquid biopsy methods are also now used in clinical
Front Office Specialist new. Diablo Valley Oncology 3.1. Walnut Creek CA 94598. Easily apply. 2 years previous experience in a busy medical office clinic or hospital setting preferred. If you have excellent communication and organizational skills and. 1 day ago. Save job.
Front Oncol. 2020 Oct 2610 578756. doi 10.3389/fonc.2020.578756. eCollection 2020.
Future Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors including our Accelerated Publication and Open Access services. Visit Oncology Central our free online community. Follow us on social media for the latest updates. Submit an article eToC Sign-up.
2 days ago · The American Society of Clinical Oncology seeks to provide the highest-quality resources in education policy the pioneering of clinical research and above all
2021-6-22 · Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐ intermediate‐1‐ intermediate‐2‐ and high‐risk myelofibrosis in JUMP a Phase 3b expanded‐access study
2021-7-5 · Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research. Recently a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments including small molecule inhibitors and
2014-8-18 · Purpose Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclophosphamide doxorubicin vincristine prednisone (CHOP) and results in a 5-year overall survival (OS) rate of less than 50 . This phase I open-label study evaluated the safety and activity of brentuximab vedotin administered sequentially with CHOP or in combination with CHP (CHOP without
BQ+ Medical not only produce components for manufacturers all over the world, but also provide private label manufacturing for leading brand distributors in different countries.
8,Cheye Road,Songjiang District,Shanghai 201611 China.
Tel: 86-021-57743953
Email: [email protected]
Copyright © BQ PLUS MEDICAL CO., LTDSitemap | Contact Us |
